From HTS to phase i: The institute for therapeutics discovery and development at the university of minnesota

Peter I. Dosa, Gunda I. Georg, Vadim J. Gurvich, Jon E. Hawkinson, Michael A. Walters, Henry L. Wong

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

The high-throughput screening core at the University of Minnesota is part of the Institute for Therapeutics Discovery and Development (ITDD), a comprehensive drug discovery and development center. The Institute provides scientific services to both academic and business communities and supports translational medicine via collaborations and contractual work. The ITDD is well-known for its broad range of screening capabilities and offers extensive medicinal chemistry expertise along with GMP scale-up and pre-clinical pharmacology support.

Original languageEnglish (US)
Pages (from-to)231-240
Number of pages10
JournalCombinatorial Chemistry and High Throughput Screening
Volume17
Issue number3
DOIs
StatePublished - Mar 2014

Keywords

  • Drug development
  • Drug discovery
  • Good manufacturing practices (GMP)
  • High throughput screening (HTS)
  • Medicinal chemistry
  • Pharmacology
  • Scale-up
  • Translational science

Fingerprint Dive into the research topics of 'From HTS to phase i: The institute for therapeutics discovery and development at the university of minnesota'. Together they form a unique fingerprint.

Cite this